Plasmodium falciparum and Plasmodium vivax demonstrate contrasting chloroquine resistance reversal phenotypes

Grennady Wirjanata, Irene Handayuni, Pak Prayoga, Leo Leonardo, Dwi Apriyanti, Leily Trianty, Ruland Wandosa, Basbak Gobay, Enny Kenangalem, Jeanne Rini Poespoprodjo, Rintis Noviyanti, Dennis E. Kyle, Qin Cheng, Ric N. Price, Jutta Marfurt

    Research output: Contribution to journalArticle

    Abstract

    High-grade chloroquine (CQ) resistance has emerged in both Plasmodium falciparum and P. vivax. The aim of the present study was to investigate the phenotypic differences of CQ resistance in both of these species and the ability of known CQ resistance reversal agents (CQRRAs) to alter CQ susceptibility. Between April 2015 and April 2016, the potential of verapamil (VP), mibefradil (MF), L703,606 (L7), and primaquine (PQ) to reverse CQ resistance was assessed in 46 P. falciparum and 34 P. vivax clinical isolates in Papua, Indonesia, where CQ resistance is present in both species, using a modified schizont maturation assay. In P. falciparum, CQ 50% inhibitory concentrations (IC50s) were reduced when CQ was combined with VP (1.4-fold), MF (1.2-fold), L7 (4.2-fold), or PQ (1.8-fold). The degree of CQ resistance reversal in P. falciparum was highly correlated with CQ susceptibility for all CQRRAs (R2 = 0.951, 0.852, 0.962, and 0.901 for VP, MF, L7, and PQ, respectively), in line with observations in P. falciparum laboratory strains. In contrast, no reduction in the CQ IC50s was observed with any of the CQRRAs in P. vivax, even in those isolates with high chloroquine IC50s. The differential effect of CQRRAs in P. falciparum and P. vivax suggests significant differences in CQ kinetics and, potentially, the likely mechanism of CQ resistance between these two species.
    Original languageEnglish
    Article numbere00355
    Pages (from-to)1-10
    Number of pages10
    JournalAntimicrobial Agents and Chemotherapy
    Volume61
    Issue number8
    Early online date22 May 2017
    DOIs
    Publication statusPublished - 25 Jul 2017

    Fingerprint Dive into the research topics of 'Plasmodium falciparum and Plasmodium vivax demonstrate contrasting chloroquine resistance reversal phenotypes'. Together they form a unique fingerprint.

  • Cite this

    Wirjanata, G., Handayuni, I., Prayoga, P., Leonardo, L., Apriyanti, D., Trianty, L., Wandosa, R., Gobay, B., Kenangalem, E., Poespoprodjo, J. R., Noviyanti, R., Kyle, D. E., Cheng, Q., Price, R. N., & Marfurt, J. (2017). Plasmodium falciparum and Plasmodium vivax demonstrate contrasting chloroquine resistance reversal phenotypes. Antimicrobial Agents and Chemotherapy, 61(8), 1-10. [e00355]. https://doi.org/10.1128/AAC.00355-17